



Diagonal Bio announces additional pilot tests of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") is pleased to announce that Diagonal Bio has signed an agreement to conduct pilot tests of the LAMPlify® platform at Stall Törnqvist as well as an undisclosed additional facility. Set to begin in April 2025, the pilot tests will run for three and six months, respectively and aim to improve equine health by enabling the early detection of potential viral infections in horses, ultimately enhancing their overall performance and well-being.

Stall Törnqvist, run by Maria Törnqvist, was founded in 2016 and currently houses 100 horses. The undisclosed facility is a prominent entity in the Swedish equine industry.

"I am intrigued to learn what LAMPlify® can do for us at Stall Törnqvist. We care about the well-being of our horses and having an easy-to-use tool to monitor their health is a very welcome addition. I look forward to evaluating the analysis tool in our stable in the coming months." – Maria Törnqvist, CEO of Stall Törnqvist

"The two new agreements regarding pilot tests of LAMPlify® will be valuable to us. We are confident that the facilities testing the LAMPlify® platform will recognise the benefits of the platform, and we are excited to showcase its full potential, as we are doing with all the facilities conducting tests." – Karin Wehlin, CEO of Diagonal Bio AB (publ)

This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 28 March, 2025, at 08:45 CET.

For additional information about Diagonal Bio, please contact:

Karin Wehlin, CEO

Phone: +46 70 305 24 88

E-mail: kw@diagonalbio.com

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.